article thumbnail

Deal value declined by 86.4 per cent in Dec 2024, compared to Dec 2023

Express Pharma

In December 2024, the pharma industry reported 82 deals worth $5.2 billion, compared to the last 12-month (December 2023 to November 2024) average of 100 deals worth $16.8 These were the three major deals that contributed 70 per cent of the total deal value during December 2024. billion; AlpInvest Partners B.V.

article thumbnail

CHMP meeting highlights – June 2024

European Pharmaceutical Review

Additionally, approval was recommended two generic medicines: Enzalutamide Viatris (enzalutamide) to treat prostate cancer, and Nilotinib Accord (nilotinib) was also recommended to treat Philadelphia chromosome positive chronic myelogenous leukaemia.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CHMP meeting highlights: January 2024

European Pharmaceutical Review

The European Medicine Agency’s human medicines committee (CHMP) recommended marketing authorisations for the regulatory approval of three medicines at its January 2024 meeting last week. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.

article thumbnail

CHMP meeting highlights: April 2024

European Pharmaceutical Review

The committee also recommended the biosimilar medicine Wezenla (ustekinumab) to treat of plaque psoriasis. Generic medicine Eribulin Baxter (eribulin) was also granted a positive opinion by the committee, to treat breast cancer and liposarcoma. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.

article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

article thumbnail

9th Advanced GMP Workshop 2024 was organised by IPA

Express Pharma

The post 9th Advanced GMP Workshop 2024 was organised by IPA appeared first on Express Pharma. It’s not just a goal; it is the foundation of our global leadership, and the trust placed in us.

article thumbnail

CHMP meeting highlights – July 2024

European Pharmaceutical Review

These medicines were recommended by the CHMP to treat plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. The post CHMP meeting highlights – July 2024 appeared first on European Pharmaceutical Review. Tuznue (trastuzumab) for breast and gastric cancer.